Search Results 31-40 of 17084 for Plasmacytoma

1. A Phase 1b/2a Multicenter, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination with Other Treatments in Subjects with Multiple Myeloma - Mayo Clinic

   Clonal bone marrow plasma cells ≥ 10% or biopsy-proven bony or extramedullary plasmacytoma. Any one or more of the following myeloma-related organ ...

2. A Study to Evaluate CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma - Mayo Clinic

   Measurable plasmacytoma by cross sectional imaging (computed tomography [CT], magnetic resonance imaging [MRI] or [18F]-fluorodeoxyglucose positron emission ...

3. Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma (KarMMa) - Mayo Clinic

   Subjects with solitary plasmacytomas or non-secretory myeloma without other evidence of measurable disease. Inadequate hepatic function defined by AST and ...

4. Publications - Udit Yadav, M.B.B.S. - Mayo Clinic

   Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas. Blood. 2023 Nov 30; 142 (22):1871-1878. View PubMed ...

5. Ide-cel, a BCMA-directed CAR-T cell therapy, shows favorable risk-benefit profile and response - Mayo Clinic

   ... plasmacytoma, higher Revised Multiple Myeloma International Staging System score or disease requiring bridging therapy during CAR -T cell manufacture. While ...

6. A Study of Investigational Immunotherapy to Determine the Safety and Effectiveness of Nivolumab and Daratumumab, with or without Pomalidomide and Dexamethasone, in Patients with Relapsed/Refractory Hematologic Malignancies - Mayo Clinic

   Solitary bone or extramedullary plasmacytoma as the only evidence of plasma cell dyscrasia;; Monoclonal gammopathy of undetermined significance (MGUS) ...

7. Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) - Mayo Clinic

   ... plasmacytomas are to have a bone marrow aspirate to obtain tumor cells; biopsy must not be considered to be more than minimal risk to the patient. NOTE ...

8. Risk Factors Associated with Clustered Plasma Cell Dyscrasias in Minnesota - Mayo Clinic

   About this study. The purpose of this study is to describe a serial of clustered plasma cell dyscrasia cases in northern Minnesota by describing the disease ...

9. A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HPN217 in Patients with Relaped/Refractory Multiple Myeloma - Mayo Clinic

   Criteria for Adverse Events (CTCAE) version 5.0 Grade ≤1. Major Exclusion Criteria: 1. Plasma cell leukemia; non-secretory myeloma (e.g., solitary plasmacytoma)

10. A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    measurable plasmacytoma (not previously irradiated); or; involved serum free light chain ≥ 10 mg/dL, with an abnormal free light chain ratio. Age ≥ 18 ...